Alkermes plc

28.03+0.1900+0.68%Vol 1.22M1Y Perf 20.99%
Oct 4th, 2023 16:00 DELAYED
BID27.54 ASK29.03
Open27.92 Previous Close27.84
Pre-Market- After-Market28.03
 - -  - -%
Target Price
31.20 
Analyst Rating
Moderate Buy 2.14
Potential %
11.31 
Finscreener Ranking
★★+     47.99
Insiders Trans % 3/6/12 mo.
-100/-88/-68 
Value Ranking
★★★     50.61
Insiders Value % 3/6/12 mo.
-100/-100/-96 
Growth Ranking
     38.60
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-96 
Income Ranking
 —    -
Price Range Ratio 52W %
52.51 
Earnings Rating
Strong Buy
Market Cap4.67B 
Earnings Date
1st Nov 2023
Alpha-0.01 Standard Deviation0.11
Beta0.60 

Today's Price Range

27.6628.21

52W Range

21.7533.71

5 Year PE Ratio Range

-33.90-17.60

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.46%
1 Month
-3.97%
3 Months
-6.85%
6 Months
-4.56%
1 Year
20.99%
3 Years
72.39%
5 Years
-37.17%
10 Years
-13.27%

TickerPriceChg.Chg.%
ALKS28.030.19000.68
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
1.80
2.20
0.27
0.39
-12.60
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
46.50
-11.90
-4.90
-10.70
-16.11
RevenueValueIndustryS&P 500US Markets
807.12M
4.91
1.38
6.75
Earnings HistoryEstimateReportedSurprise %
Q02 20230.280.3835.71
Q01 2023-0.19-0.1047.37
Q04 2022-0.10-0.0280.00
Q03 2022-0.13-0.14-7.69
Q02 2022-0.12-0.0833.33
Q01 2022-0.140.01107.14
Q04 2021-0.030.13533.33
Q03 2021-0.05-0.0260.00
Earnings Per EndEstimateRevision %Trend
9/2023 QR0.3182.35Positive
12/2023 QR0.4053.85Positive
12/2023 FY0.9451.61Positive
12/2024 FY1.47-18.33Negative
Next Report Date1st Nov 2023
Estimated EPS Next Report0.31
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.22M
Shares Outstanding166.56K
Shares Float165.36M
Trades Count13.54K
Dollar Volume34.07M
Avg. Volume1.48M
Avg. Weekly Volume1.45M
Avg. Monthly Volume1.35M
Avg. Quarterly Volume1.65M

Alkermes plc (NASDAQ: ALKS) stock closed at 28.03 per share at the end of the most recent trading day (a 0.68% change compared to the prior day closing price) with a volume of 1.22M shares and market capitalization of 4.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2245 people. Alkermes plc CEO is Richard F. Pops.

The one-year performance of Alkermes plc stock is 20.99%, while year-to-date (YTD) performance is 7.27%. ALKS stock has a five-year performance of -37.17%. Its 52-week range is between 21.75 and 33.71, which gives ALKS stock a 52-week price range ratio of 52.51%

Alkermes plc currently has a PE ratio of -34.80, a price-to-book (PB) ratio of 4.27, a price-to-sale (PS) ratio of 5.32, a price to cashflow ratio of 86.70, a PEG ratio of -1.69, a ROA of -7.11%, a ROC of -8.32% and a ROE of -13.10%. The company’s profit margin is -16.11%, its EBITDA margin is -4.90%, and its revenue ttm is $807.12 Million , which makes it $4.91 revenue per share.

Of the last four earnings reports from Alkermes plc, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.31 for the next earnings report. Alkermes plc’s next earnings report date is 01st Nov 2023.

The consensus rating of Wall Street analysts for Alkermes plc is Moderate Buy (2.14), with a target price of $31.2, which is +11.31% compared to the current price. The earnings rating for Alkermes plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alkermes plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alkermes plc has a Sell technical analysis rating based on Technical Indicators (ADX : 8.87, ATR14 : 0.72, CCI20 : -152.46, Chaikin Money Flow : -0.01, MACD : -0.27, Money Flow Index : 30.95, ROC : -5.95, RSI : 37.41, STOCH (14,3) : 4.73, STOCH RSI : 0.00, UO : 44.56, Williams %R : -95.27), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alkermes plc in the last 12-months were: Blair C. Jackson (Option Excercise at a value of $0), Blair Curtis Jackson (Option Excercise at a value of $0), Brown Iain (Option Excercise at a value of $0), Cato T. Laurencin (Sold 0 shares of value $-124 911 ), Cato T. Laurencin (Sold 5 438 shares of value $172 220 ), Christian Todd Nichols (Option Excercise at a value of $401 123), Christian Todd Nichols (Sold 27 134 shares of value $784 987 ), Craig C. Hopkinson (Option Excercise at a value of $0), Daglio David (Sold 0 shares of value $0 ), David A. Daglio (Buy at a value of $815 735), David Joseph Gaffin (Option Excercise at a value of $0), Gaffin David (Option Excercise at a value of $0), Hopkinson Craig (Option Excercise at a value of $0), Iain M. Brown (Option Excercise at a value of $0), Landine Michael (Option Excercise at a value of $0), Mckeon Brian (Sold 0 shares of value $0 ), Michael J. Landine (Option Excercise at a value of $0), Pops Richard (Option Excercise at a value of $0), Richard F. Pops (Option Excercise at a value of $0), Wysenski Nancy (Option Excercise at a value of $1 284 113), Wysenski Nancy (Sold 41 250 shares of value $1 288 650 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (42.86 %)
3 (42.86 %)
4 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (57.14 %)
4 (57.14 %)
4 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.14
Moderate Buy
2.14
Moderate Buy
2.00

Alkermes plc

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

CEO: Richard F. Pops

Telephone: +353 17728000

Address: 1 Burlington Road, Dublin D04 C5Y6, , IE

Number of employees: 2 245

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

56%44%

Bearish Bullish

62%38%

 

TipRanks News for ALKS

Mon, 24 Jul 2023 08:30 GMT Analysts Top Healthcare Picks: Alkermes (ALKS), CymaBay Therapeutics (CBAY)

- TipRanks. All rights reserved.

News

Stocktwits